2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
2
Active not recruiting
2
Terminated
1
Suspended
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
47
Breast Neoplasms
46
Colorectal Neoplasms
28
Prostatic Neoplasms
26
Carcinoma, Non-Small-Cell Lung
21
Leukemia, Myeloid, Acute
19
Glioblastoma
19
Pancreatic Neoplasms
17
Melanoma
17
Lung Neoplasms
17
Neoplasm Metastasis
16
Glioma
14
Stomach Neoplasms
13
Carcinoma, Hepatocellular
13
Brain Neoplasms
13
Ovarian Neoplasms
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Myelodysplastic Syndromes
11
Triple Negative Breast Neoplasms
10
Multiple Myeloma
10
Head and Neck Neoplasms
10
Carcinoma, Renal Cell
10
Lymphoma
9
Uterine Cervical Neoplasms
7
Rectal Neoplasms
7
Hematologic Neoplasms
7
Esophageal Neoplasms
7
Colonic Neoplasms
7
Sarcoma
6
Leukemia
6
Interventions
talazoparib
1
CX 5461
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Suspended
×
Metastatic Castration Resistant Prostate Cancer (mCRPC)
×
Clear all
NCT05425862
2023-12-11
REPAIR
Peter MacCallum Cancer Centre, Australia
Phase 1
Suspended
48 enrolled